Heparan sulfate antibodies applications guide
New 24-page guide that brings together applications, protocols, results and citations for researchers.
Amsbio has produced a new 24-page guide that brings together applications, protocols, results and citations to provide an informative resource for researchers using heparan sulfate antibodies.
Heparan Sulfate (HS) is synthesized as the glycosaminoglycan (GAG) component of heparan sulfate proteoglycans (HSPGs). It is expressed on the cell surface of virtually all cell types and basement membranes. It displays specific interactions with many biologically active proteins and, thus is involved in many important biological processes. Many researchers are interested in examining the dynamic distribution of HSPG in tissues and also analyzing HS structures to elucidate the biological functions of HSPG. The non-immunogenic character of HS makes this type of antibody difficult to raise, so the few hybridoma-derived mouse anti-HS antibodies such as JM403, 10E4 and 3G10 are valuable tools for HS research. Using multiple HS antibodies that recognize subtle differences in HS patterning can be useful in applications such as flow cytometry allowing multiple cell types to be directly compared.
Amsbio offers a suite of high quality heparan sulfate antibodies from the important clones F69-3G10, F58-10E4 and JM403. These antibodies are ideal for targeted binding of HS for HSPG research and provide a range of anti-HS antibodies recognizing distinct HS substructures, which have been well-characterized in previous studies. The guide provides an informative introduction to applications of JM403, 10E4 and 3G10 Heparan Sulfate antibodies; including use of the 10E4 and JM-403 clones together in ELISA to detect or measure HS. GAGs are not species-specific, so in common with AMSBIO’s other GAG antibodies, the clones featured in this guide react across a wide range of species.
Johan van der Vlag, Associate Professor at Radboud University Medical Center, Nijmegen commented: “I am extremely happy to see that our JM403 clone is commercially available to serve the scientific community that studies the role of GAGs in normal physiology and pathology. Since we only want to licence our antibody to a company that is dedicated to glycobiology and in particular GAGs, AMSBIO was our only choice.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance